Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellectis S.A., a foreign private issuer, on December 5, 2025. The filing serves as a re-submission of Exhibit 4.1.3 (Third Amendment to the Exclusive Patent License Agreement with the Regents of the University of Minnesota, dated December 16, 2015) to comply with Item 601(b) of Regulation S-K. The purpose is to omit confidential information that is not material but could cause competitive harm if disclosed, without requiring a confidential treatment request. The filing also incorporates previously re-filed Exhibits 4.1, 4.1.1, and 4.1.2.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding contract exhibits and contains no financial statements or performance data.
Material Changes
There are no material changes to financial performance or operations reported in this filing. The only change is the administrative re-filing of a historical patent license amendment with redacted confidential information.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The only risk noted is the potential competitive harm that would result from the public disclosure of specific confidential terms within the patent license agreement.
Key Facts for Investor Verification
- The filing is administrative in nature and does not contain new financial results.
- Exhibit 4.1.3 (Third Amendment to the University of Minnesota Patent License) has been re-filed with redactions.
- Confidential information was omitted under Regulation S-K Item 601(b)(10)(iv) as it is deemed not material but competitively sensitive.
- The filing is incorporated by reference into multiple active registration statements (Forms F-3 and S-8).